Bal Pharma
Bal Pharma Performance
Day Range
- Low 93.1
- High 96.9
52 Week Range
- Low 63.35
- High 106.5
- Open Price94.15
- Previous Close95.55
- Volume16836
Start SIP in Bal Pharma
Start SIPBal Pharma Investment Rating
-
Master Rating:
-
Bal Pharma has an operating revenue of Rs. 304.76 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 2% needs improvement, ROE of 4% is fair but needs improvement. The company has a reasonable debt to equity of 48%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 10% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 10% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 17 which is a POOR score indicating inconsistency in earnings, a RS Rating of 42 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 114 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 70 | 82 | 77 | 75 | 70 | 74 |
| Operating Expenses Qtr Cr | 63 | 74 | 70 | 69 | 64 | 70 |
| Operating Profit Qtr Cr | 7 | 8 | 6 | 6 | 5 | 3 |
| Depreciation Qtr Cr | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest Qtr Cr | 4 | 4 | 3 | 3 | 2 | 2 |
| Tax Qtr Cr | 0 | 1 | 0 | 0 | 0 | 0 |
| Net Profit Qtr Cr | 1 | 2 | 1 | 1 | 1 | 3 |
Bal Pharma Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 12
- Bearish Moving Average
- ___
- 4
- 20 Day
- ₹95.19
- 50 Day
- ₹94.65
- 100 Day
- ₹92.2
- 200 Day
- ₹90.4
- 20 Day
- ₹95.65
- 50 Day
- ₹95.76
- 100 Day
- ₹92.4
- 200 Day
- ₹86.31
Bal Pharma Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹97.04 |
| Second Resistance | ₹98.87 |
| Third Resistance | ₹100.84 |
| RSI | 49.83 |
| MFI | 41.93 |
| MACD Single Line | -0.18 |
| MACD | -0.26 |
| Support | |
|---|---|
| First Resistance | ₹93.24 |
| Second Resistance | ₹91.27 |
| Third Resistance | ₹89.44 |
Bal Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 22,496 | 1,163,493 | 51.72 |
| Week | 16,126 | 950,481 | 58.94 |
| 1 Month | 36,764 | 2,240,419 | 60.94 |
| 6 Month | 78,087 | 3,535,779 | 45.28 |
Bal Pharma Result Highlights
Bal Pharma Synopsis
NSE-Medical-Diversified
Bal Pharma Ltd belongs to the Industry of Pharmaceuticals. Company’s Total Operating Revenue is Rs. 303.10 Cr. and Equity Capital is Rs. 15.69 Cr. for the Year ended 31/03/2023. Bal Pharma Ltd. is a Public Limited Listed company incorporated on 19/05/1987 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L85110KA1987PLC008368 and registration number is 008368.| Market Cap | 149 |
| Sales | 304 |
| Shares in Float | 0.75 |
| No of funds | 1 |
| Yield | 1.05 |
| Book Value | 1.54 |
| U/D Vol ratio | 1.9 |
| LTDebt / Equity | 32 |
| Alpha | 0.04 |
| Beta | 0.17 |
Bal Pharma
| Owner Name | Jun-23 | Mar-23 | Dec-22 |
|---|---|---|---|
| Promoters | 51.61% | 51.61% | 51.61% |
| Foreign Portfolio Investors | 0.17% | 0.17% | 0.18% |
| Individual Investors | 31.99% | 32.07% | 32.13% |
| Others | 16.23% | 16.15% | 16.08% |
Bal Pharma Management
| Name | Designation |
|---|---|
| Mr. Shailesh D Siroya | Managing Director |
| Mr. Himesh Virupakshaya | Executive Director |
| Mr. Jatish Sheth | Independent Director |
| Dr. C V Srinivas | Independent Director |
| Ms. Nicloa Neeladri | Independent Director |
| Mr. H S Venkatesh | Additional Director |
| Mr. Kotian Chittananda Damodar | Additional Director |
Bal Pharma Forecast
Price Estimates
Bal Pharma Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-08-11 | Quarterly Results & A.G.M. | |
| 2023-05-29 | Audited Results & Final Dividend | |
| 2023-02-06 | Quarterly Results | |
| 2022-11-14 | Quarterly Results & ESOP | Inter alia, To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd. a wholly owned subsidiary of the Company. per share(10%)Final Dividend |
| 2022-08-11 | Quarterly Results |
- Company Name
- CMP
- Chg(%)
- Bajaj Finance
- 7968
- 2.0
- Larsen & Toubro
- 3073
- 1.6
- Titan Company
- 3196
- 1.5
- Bajaj Finserv
- 1561
- 1.4
- Adani Ports
- 831
- 0.8
- Company Name
- CMP
- Chg(%)
- O N G C
- 185
- -3.8
- Eicher Motors
- 3351
- -2.8
- Hindalco Inds.
- 480
- -2.6
- Maruti Suzuki
- 10347
- -2.5
- Dr Reddys Labs
- 5462
- -2.2
Bal Pharma FAQs
What is Share Price of Bal Pharma ?
Bal Pharma share price is ₹95 As on 04 October, 2023 | 04:31
What is the Market Cap of Bal Pharma ?
The Market Cap of Bal Pharma is ₹149.4 Cr As on 04 October, 2023 | 04:31
What is the P/E ratio of Bal Pharma ?
The P/E ratio of Bal Pharma is 62.6 As on 04 October, 2023 | 04:31
What is the PB ratio of Bal Pharma ?
The PB ratio of Bal Pharma is 2.3 As on 04 October, 2023 | 04:31